← back to search

Mark Dunning

Insigneo · GB
Area of research
Molecular Biology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Gene expression and cancer classification, Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, and Genomics and Chromatin Dynamics.
h-index
35
citations
19,307
works
105
NIH funding
primary concept
email

Recent publications

JAG1-NOTCH4 mechanosensing drives atherosclerosis
Science Advances 2022cited by 37position: middledoi
Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
Nature Communications 2021cited by 54position: middledoi
Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome
American Journal of Respiratory and Critical Care Medicine 2020cited by 72position: middledoi
Mining Human Prostate Cancer Datasets: The “camcAPP” Shiny App
EBioMedicine 2017cited by 36position: firstdoi
Corrigendum to “Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study” [EBioMedicine 2 (9) (2015) 1133–1144]
EBioMedicine 2017cited by 3position: middledoi
Mining human prostate cancer datasets: The “camcAPP” shiny app
bioRxiv (Cold Spring Harbor Laboratory) 2017cited by 2position: firstdoi
Gene regulatory mechanisms underpinning prostate cancer susceptibility
Nature Genetics 2016cited by 131position: middledoi
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study
EBioMedicine 2015cited by 323position: middledoi
The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
European Urology 2015cited by 66position: middledoi
HES5 silencing is an early and recurrent change in prostate tumourigenesis
Endocrine Related Cancer 2015cited by 13position: middledoi
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
The Lancet Oncology 2014cited by 351position: middledoi
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Genome biology 2014cited by 223position: middledoi
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer
Molecular Oncology 2014cited by 60position: middledoi
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Genome Biology 2014cited by 11position: middledoi
935 The Timing of Oncogenic Events in the Evolution of the Oesophageal Adenocarcinoma Genome and Implications for Clinical Diagnostics
Gastroenterology 2014cited by 0position: middledoi
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
New England Journal of Medicine 2013cited by 2,195position: middledoi
Loss of centrioles causes chromosomal instability in vertebrate somatic cells
The Journal of Cell Biology 2013cited by 136position: middledoi
Neo-tAnGo science: A translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy.
Journal of Clinical Oncology 2013cited by 2position: middledoi
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Nature 2012cited by 6,340position: middledoi
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Nature 2012cited by 2,352position: middledoi
Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling
Science Translational Medicine 2012cited by 429position: middledoi
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
Breast Cancer Research 2012cited by 33position: middledoi
Calling Sample Mix-Ups in Cancer Population Studies
PLoS ONE 2012cited by 10position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Suet‐Feung Chin · Cancer Research UK Cambridge Center8 papers (2012–2014)Carlos Caldas · Concern Foundation8 papers (2012–2014)Andy G. Lynch · University of St Andrews7 papers (2012–2017)Alastair Lamb · Cambridge University Hospitals NHS Foundation Trust7 papers (2015–2017)Helen Ross‐Adams · Cancer Research UK Cambridge Center7 papers (2015–2017)Ian G. Mills · University of Manchester6 papers (2015–2017)Oscar M. Rueda · University of Cambridge6 papers (2012–2014)Christina Curtis · Stanford University5 papers (2012–2014)David E. Neal · University of Oxford5 papers (2015–2017)Jonathan Kay · The University of Texas Southwestern Medical Center4 papers (2015–2017)Antonio Ramos‐Montoya · Cancer Research UK Cambridge Center4 papers (2015–2017)Anne Y. Warren · University of Cambridge4 papers (2015–2016)Charles Massie · University of Cambridge4 papers (2015–2017)Samuel Aparício · BC Cancer Agency4 papers (2012–2014)Hayley C. Whitaker · University College London4 papers (2015–2017)Henrik Grönberg · Karolinska Institutet3 papers (2015–2017)H. Raza Ali · University of Cambridge3 papers (2012–2014)Silvia Halim · Cancer Research UK Cambridge Center3 papers (2015–2017)Elena Provenzano · Cambridge University Hospitals NHS Foundation Trust3 papers (2012–2014)Lars Egevad · Karolinska Institutet3 papers (2015–2017)